IFNAR1 and dermatomyositis: Two DM patients with high Siglec-1 MFI were treated with the selective type-I interferon receptor (IFNAR1) inhibitor anifrolumab, which resulted in a rapid, major improvement based on Total Improvement Score (TIS).